{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T07:29:06Z","timestamp":1761290946516},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2011,1,18]],"date-time":"2011-01-18T00:00:00Z","timestamp":1295308800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2011,6]]},"DOI":"10.1007\/s10147-010-0176-0","type":"journal-article","created":{"date-parts":[[2011,1,17]],"date-time":"2011-01-17T05:21:46Z","timestamp":1295241706000},"page":"257-263","source":"Crossref","is-referenced-by-count":19,"title":["Splenomegaly in FOLFOX-na\u00efve stage IV or recurrent colorectal cancer patients due to chemotherapy-associated hepatotoxicity can be predicted by the aspartate aminotransferase to platelet ratio before chemotherapy"],"prefix":"10.1007","volume":"16","author":[{"given":"Kazuhiro","family":"Miura","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Nakano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joe","family":"Sakurai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinjiro","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Satoshi","family":"Koizumi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuhiro","family":"Arai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tsukasa","family":"Shimamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryoji","family":"Makizumi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kyoji","family":"Yamada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuyoshi","family":"Miyajima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takehito","family":"Otsubo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junki","family":"Koike","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2011,1,18]]},"reference":[{"key":"176_CR1","doi-asserted-by":"crossref","first-page":"2938","DOI":"10.1200\/JCO.2000.18.16.2938","volume":"18","author":"A Gramont de","year":"2000","unstructured":"de Gramont A, Figer A, Seymour M et al (2000) Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol 18:2938\u20132947","journal-title":"J Clin Oncol"},{"key":"176_CR2","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1093\/annonc\/mdn557","volume":"20","author":"E Aranda","year":"2009","unstructured":"Aranda E, Valladares M, Martinez-Villacampa M et al (2009) Randomized study of weekly irinotecan plus high-dose 5-fluorouracil (FUIRI) versus biweekly irinotecan plus 5-fluorouracil\/leucovorin (FOLFIRI) as first-line chemotherapy for patients with metastatic colorectal cancer: a Spanish Cooperative Group for the Treatment of Digestive Tumors Study. Ann Oncol 20:251\u2013257","journal-title":"Ann Oncol"},{"key":"176_CR3","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1093\/annonc\/mdi193","volume":"16","author":"HP Kalofonos","year":"2005","unstructured":"Kalofonos HP, Aravantinos G, Kosmidis P et al (2005) Irinotecan or oxaliplatin combined with leucovorin and 5-fluorouracil as first-line treatment in advanced colorectal cancer: a multicenter, randomized, phase II study. Ann Oncol 16:869\u2013877","journal-title":"Ann Oncol"},{"key":"176_CR4","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1200\/JCO.2006.09.6305","volume":"25","author":"BJ Giantonio","year":"2007","unstructured":"Giantonio BJ, Catalano PJ, Meropol NJ et al (2007) Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 25:1539\u20131544","journal-title":"J Clin Oncol"},{"key":"176_CR5","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa032691","volume":"350","author":"H Hurwitz","year":"2004","unstructured":"Hurwitz H, Fehrenbacher L, Novotny W et al (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335\u20132342","journal-title":"N Engl J Med"},{"key":"176_CR6","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1016\/S0140-6736(08)60455-9","volume":"371","author":"B Nordlinger","year":"2008","unstructured":"Nordlinger B, Sorbye H, Glimelius B et al (2008) Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet 371:1007\u20131016","journal-title":"Lancet"},{"key":"176_CR7","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1097\/01.sla.0000145964.08365.01","volume":"240","author":"R Adam","year":"2004","unstructured":"Adam R, Delvart V, Pascal G et al (2004) Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg 240:644\u2013657 (discussion 657\u2013658)","journal-title":"Ann Surg"},{"key":"176_CR8","doi-asserted-by":"crossref","first-page":"5344","DOI":"10.1200\/JCO.2008.17.5299","volume":"26","author":"DG Blazer 3rd","year":"2008","unstructured":"Blazer DG 3rd, Kishi Y, Maru DM et al (2008) Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases. J Clin Oncol 26:5344\u20135351","journal-title":"J Clin Oncol"},{"key":"176_CR9","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1016\/j.jamcollsurg.2005.01.024","volume":"200","author":"FG Fernandez","year":"2005","unstructured":"Fernandez FG, Ritter J, Goodwin JW et al (2005) Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on resectability of hepatic colorectal metastases. J Am Coll Surg 200:845\u2013853","journal-title":"J Am Coll Surg"},{"key":"176_CR10","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1093\/annonc\/mdh095","volume":"15","author":"L Rubbia-Brandt","year":"2004","unstructured":"Rubbia-Brandt L, Audard V, Sartoretti P et al (2004) Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann Oncol 15:460\u2013466","journal-title":"Ann Oncol"},{"key":"176_CR11","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1200\/JCO.2005.05.3074","volume":"24","author":"JN Vauthey","year":"2006","unstructured":"Vauthey JN, Pawlik TM, Ribero D et al (2006) Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol 24:2065\u20132072","journal-title":"J Clin Oncol"},{"key":"176_CR12","doi-asserted-by":"crossref","first-page":"4983","DOI":"10.1200\/JCO.2006.05.8156","volume":"24","author":"T Aloia","year":"2006","unstructured":"Aloia T, Sebagh M, Plasse M et al (2006) Liver histology and surgical outcomes after preoperative chemotherapy with fluorouracil plus oxaliplatin in colorectal cancer liver metastases. J Clin Oncol 24:4983\u20134990","journal-title":"J Clin Oncol"},{"key":"176_CR13","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1097\/SLA.0b013e31815774de","volume":"247","author":"H Nakano","year":"2008","unstructured":"Nakano H, Oussoultzoglou E, Rosso E et al (2008) Sinusoidal injury increases morbidity after major hepatectomy in patients with colorectal liver metastases receiving preoperative chemotherapy. Ann Surg 247:118\u2013124","journal-title":"Ann Surg"},{"key":"176_CR14","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1097\/00004728-200009000-00022","volume":"24","author":"S Watanabe","year":"2000","unstructured":"Watanabe S, Hosomi N, Kitade Y et al (2000) Assessment of the presence and severity of esophagogastric varices by splenic index in patients with liver cirrhosis. J Comput Assist Tomogr 24:788\u2013794","journal-title":"J Comput Assist Tomogr"},{"key":"176_CR15","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1111\/j.1478-3231.2006.01356.x","volume":"26","author":"ER Parise","year":"2006","unstructured":"Parise ER, Oliveira AC, Figueiredo-Mendes C et al (2006) Noninvasive serum markers in the diagnosis of structural liver damage in chronic hepatitis C virus infection. Liver Int 26:1095\u20131099","journal-title":"Liver Int"},{"key":"176_CR16","doi-asserted-by":"crossref","first-page":"569","DOI":"10.2169\/internalmedicine.47.0595","volume":"47","author":"CS Lin","year":"2008","unstructured":"Lin CS, Chang CS, Yang SS et al (2008) Retrospective evaluation of serum markers APRI and AST\/ALT for assessing liver fibrosis and cirrhosis in chronic hepatitis B and C patients with hepatocellular carcinoma. Intern Med 47:569\u2013575","journal-title":"Intern Med"},{"key":"176_CR17","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1002\/bjs.5719","volume":"94","author":"D Zorzi","year":"2007","unstructured":"Zorzi D, Laurent A, Pawlik TM et al (2007) Chemotherapy-associated hepatotoxicity and surgery for colorectal liver metastases. Br J Surg 94:274\u2013286","journal-title":"Br J Surg"},{"key":"176_CR18","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1097\/01.sla.0000251747.80025.b7","volume":"245","author":"L McCormack","year":"2007","unstructured":"McCormack L, Petrowsky H, Jochum W et al (2007) Hepatic steatosis is a risk factor for postoperative complications after major hepatectomy: a matched case\u2013control study. Ann Surg 245:923\u2013930","journal-title":"Ann Surg"},{"key":"176_CR19","doi-asserted-by":"crossref","unstructured":"Wicherts D, de Haas R, Sebagh M et al (2009) Liver regenerative nodular hyperplasia consecutive to preoperative chemotherapy: impact on outcome of liver surgery for colorectal metastases. J Clin Oncol 27(15s):suppl (abstr 4097)","DOI":"10.1200\/jco.2009.27.15_suppl.4097"},{"key":"176_CR20","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/S1470-2045(09)70064-6","volume":"10","author":"YS Chun","year":"2009","unstructured":"Chun YS, Laurent A, Maru D et al (2009) Management of chemotherapy-associated hepatotoxicity in colorectal liver metastases. Lancet Oncol 10:278\u2013286","journal-title":"Lancet Oncol"},{"key":"176_CR21","doi-asserted-by":"crossref","unstructured":"Nakano H, Ossoutzoglou E, Rosso E et al (2008) Blue liver syndrome increases morbidity after right hepatectomy in patients with colorectal liver metastases receiving preoperative chemotherapy. In: HPB, 8th world congress of the IHPBA, vol 10, suppl (abstr 1)","DOI":"10.1097\/SLA.0b013e31815774de"},{"key":"176_CR22","doi-asserted-by":"crossref","first-page":"4304","DOI":"10.1200\/JCO.2008.16.1893","volume":"26","author":"J Ward","year":"2008","unstructured":"Ward J, Guthrie JA, Sheridan MB et al (2008) Sinusoidal obstructive syndrome diagnosed with superparamagnetic iron oxide-enhanced magnetic resonance imaging in patients with chemotherapy-treated colorectal liver metastases. J Clin Oncol 26:4304\u20134310","journal-title":"J Clin Oncol"},{"issue":"1\u20134","key":"176_CR23","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1007\/s12029-009-9063-1","volume":"39","author":"E Oki","year":"2008","unstructured":"Oki E, Kakeji Y, Taketomi A et al (2008) Transient elastography for the prediction of oxaliplatin-associated liver injury in colon cancer patients: a preliminary analysis. J Gastrointest Cancer 39(1\u20134):82\u201385","journal-title":"J Gastrointest Cancer"},{"key":"176_CR24","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1159\/000210025","volume":"76","author":"R Angitapalli","year":"2009","unstructured":"Angitapalli R, Litwin AM, Kumar PR et al (2009) Adjuvant FOLFOX chemotherapy and splenomegaly in patients with stages II\u2013III colorectal cancer. Oncology 76:363\u2013368","journal-title":"Oncology"},{"key":"176_CR25","doi-asserted-by":"crossref","first-page":"2549","DOI":"10.1200\/JCO.2009.27.5701","volume":"28","author":"MJ Overman","year":"2010","unstructured":"Overman MJ, Maru DM, Charnsangavej C et al (2010) Oxaliplatin-mediated increase in spleen size as a biomarker for the development of hepatic sinusoidal injury. J Clin Oncol 28:2549\u20132555","journal-title":"J Clin Oncol"},{"key":"176_CR26","doi-asserted-by":"crossref","first-page":"5254","DOI":"10.1200\/JCO.2008.17.7857","volume":"26","author":"SB Kesmodel","year":"2008","unstructured":"Kesmodel SB, Ellis LM, Lin E et al (2008) Preoperative bevacizumab does not significantly increase postoperative complication rates in patients undergoing hepatic surgery for colorectal cancer liver metastases. J Clin Oncol 26:5254\u20135260","journal-title":"J Clin Oncol"},{"key":"176_CR27","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.jamcollsurg.2007.06.290","volume":"206","author":"SK Reddy","year":"2008","unstructured":"Reddy SK, Morse MA, Hurwitz HI et al (2008) Addition of bevacizumab to irinotecan- and oxaliplatin-based preoperative chemotherapy regimens does not increase morbidity after resection of colorectal liver metastases. J Am Coll Surg 206:96\u2013106","journal-title":"J Am Coll Surg"},{"key":"176_CR28","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.ejso.2008.12.013","volume":"35","author":"M Klinger","year":"2009","unstructured":"Klinger M, Eipeldauer S, Hacker S et al (2009) Bevacizumab protects against sinusoidal obstruction syndrome and does not increase response rate in neoadjuvant XELOX\/FOLFOX therapy of colorectal cancer liver metastases. Eur J Surg Oncol 35:515\u2013520","journal-title":"Eur J Surg Oncol"},{"key":"176_CR29","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1200\/JCO.2007.11.6566","volume":"26","author":"G Buren Van 2nd","year":"2008","unstructured":"Van Buren G 2nd, Yang AD, Dallas NA et al (2008) Effect of molecular therapeutics on liver regeneration in a murine model. J Clin Oncol 26:1836\u20131842","journal-title":"J Clin Oncol"},{"key":"176_CR30","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1245\/s10434-009-0447-z","volume":"16","author":"B Aussilhou","year":"2009","unstructured":"Aussilhou B, Dokmak S, Faivre S et al (2009) Preoperative liver hypertrophy induced by portal flow occlusion before major hepatic resection for colorectal metastases can be impaired by bevacizumab. Ann Surg Oncol 16:1553\u20131559","journal-title":"Ann Surg Oncol"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-010-0176-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10147-010-0176-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-010-0176-0","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,11,17]],"date-time":"2021-11-17T14:14:53Z","timestamp":1637158493000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10147-010-0176-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2011,1,18]]},"references-count":30,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2011,6]]}},"alternative-id":["176"],"URL":"https:\/\/doi.org\/10.1007\/s10147-010-0176-0","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,1,18]]}}}